We have a broad portfolio covering a wide range of therapeutic areas, and across modalities, from small molecules to cell therapy. Many have already attracted investments from top-tier investors such as Pureos Bioventures, NEA, Orbimed, Syncona, Sofinnova, the Novartis Venture Fund, Biomedinvest, Boehringer Ingelheim Venture Fund, Kurma Partners, Sunstone Life Science Ventures, Ysios Capital, Morningside Venture Investments, Jeito Capital, Versant Ventures, Novo Holdings, RA Capital Management and others.
Financed: $50M raisedÂ
Combining cell-shielding and immunotherapies to safely treat hematologic disorders, targeting diseased cells while preserving healthy ones and resisting immunotherapy depletion
Financed: $366M raised
Anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies to treat cancer and reverse fibrosis
Financed: $155M raised
Cytokine based cancer therapies harnessing the power of the immune system
Financed: $35M raised
mRNA platform for local regenerative medicine-based therapeutics
Incubating
A novel class of oral immunosuppressive therapies for chronic T cell-mediated autoimmune diseases
Financed: $39M raised
Developing small molecule inhibitors addressing non mutational mechanisms of cancer therapy evasion
Acquired by Repertoire Immune Medicines
Functional ID of (neo)antigens for cancer, immunological and infectious diseases.
Financed: $42M raised
Acquired by BI for $507M
Intracellular delivery of therapeutic payloads using bacteria, exploiting bacterial tumor targeting
Seed
Bacterial mixes as microbiome therapeutics in IBD and oncology based on mixed-culture technology
Incubating
Cyclic short peptides platform for the selective capturing of metal ions in metal-related pathologies
Financed: $41.5M raised
Stopped
Glycomimetic platform for removing auto-antibodies in autoimmune neuropathies
Financed
Developing gene logic circuits to accurately identify complex disease patterns and enable in-vivo cancer cell targeting and treatment
Incubating
Native proteins-derived biologics platform to produce high-affinity and low-immunogenicity therapeutics for autoimmune diseases
Stopped
First-in-class therapeutics to stop neurodegenerative diseases with a selective small molecule approach
Incubating
Leveraging an AI-driven discovery platform for highly specific inhibition of mTOR and hard to drug targets
Financed: $16M raised
Highly potent, targeted soluble T cell receptor therapies for solid tumors, using AI-guided engineering to enhance affinity, stability, and safety
Seed / Incubating
Platform to create compartment locked biologics for higher local retention and fast systemic degradation
Seed / Incubating
Antibody-based discovery platform against novel druggable secreted growth factors reprogramming diseased cells towards uncontrolled growth
Incubating
Novel approach to safely restore microtubule function for cardiovascular and neurodegenerative diseases
Financed
Breaking efficacy ceilings in inflammatory and autoimmune diseases
Incubating
RNA-based therapeutics targeting mitochondrial function and ER stress for liver disease treatment
Stopped
Developing novel inflammasome inhibitors
Financed: $25M raised
First-in-class endocannabinoid modulators to restore brain function in CNS disorders, targeting stress, anxiety, and related conditions
Incubating
Targeting endometriosis and other chronic fibro-inflammatory disease with immunotherapy solutions
Incubating
Antibodies against novel stromal cell targets acting locally on the immune system to treat chronic immune-mediated diseases
Incubating
Modulating muscle secretome-derived novel targets for the treatment of metabolic diseases
